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Abstract
Hepatitis B virus (HBV) infection is associated with chronic liver diseases (CLD), which 
progress from hepatitis to fibrosis, cirrhosis, and finally hepatocellular carcinoma (HCC) 
over 30–50 years. The pathogenesis of CLD is immune mediated, which is character-
ized by persistent immune responses against virus infected hepatocytes. During bouts of 
CLD, the virus gene encoding the hepatitis B x antigen (HBx) is increasingly found inte-
grated at multiple sites within the human genome. Many of these integrated templates 
express HBx, which is a trans-regulatory protein that supports virus gene expression and 
replication on one hand, but also alters patterns of gene expression in the infected cell. 
HBx alters gene expression by constitutively activating signal transduction pathways in 
the cytoplasm and promoting epigenetic mediated changes in the expression of cellular 
genes. In doing so, HBx contributes to the persistence of virus infected cells and to the 
pathogenesis of CLD by triggering multiple hallmarks which are characteristic of cancer.
Keywords: hepatitis B virus, chronic liver disease, hepatocellular carcinoma,  
hepatitis B x, immune mediated liver disease, epigenetics, hallmarks of cancer
1. Introduction
Hepatitis B virus (HBV) is a blood-borne virus that infects the liver. Until the discovery of the 
virus in the 1960s [1], it was transmitted sexually and by transfusion of contaminated blood 
and blood fractions. Today, the virus has been virtually eliminated from the blood supply by a 
simple blood test while infection has been prevented by a highly efficacious vaccine [2, 3]. Prior 
to establishment of vaccination programs in various countries, infants born to infected mothers 
replicating virus often acquired the virus at birth by exposure to contaminated maternal blood. 
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More than 90% of these children became HBV carriers, characterized by the persistence of 
virus or virus antigens in their blood for years to decades. These children were a high risk for 
the development of chronic liver disease (CLD), which progressed from hepatitis, to fibrosis, 
cirrhosis, and hepatocellular carcinoma (HCC) [4]. Fortunately, newborns in many countries 
receive the HBV vaccine at birth, which helps to prevent mother-to-infant transmission as well 
as protect from exposure later in life. Among unvaccinated adults engaging in unprotected 
sex, roughly 5–10% become carriers, and these individuals are also at high risk for the develop-
ment of CLD and HCC. Although estimates vary, there are ~300–350 million carriers of HBV 
worldwide [5]. HCC is the sixth most prevalent cancer worldwide, with about 600,000 newly 
diagnosed cases annually, and the second leading cause of cancer deaths [6]. Interferon, and 
in more recent years, powerful nucleoside analogs, have successfully treated patients with 
chronic hepatitis B, but presently there is no cure [7, 8]. HCC is curable by surgical resection, 
but this is often accompanied by relapse. Dozens of drugs, alone or in combination, have been 
evaluated in clinical trials for patients with advanced HCC, but only the multi-kinase inhibi-
tors, Sorafenib and regorafenib, and the immune checkpoint inhibitor nivolumab, have been 
useful in modestly extending the lifespan of such patients [9, 10]. Given that the carrier state 
and CLD are the major risk factors for HCC [11], there is strong rationale to better understand 
the host-virus relationship that contributes to the pathogenesis of chronic infection.
2. Variations in pathogenesis
A hallmark in the pathogenesis of HBV infection is its’ variability. Among acutely infected 
adults, up to 65% develop a subclinical infection characterized only by the appearance of one 
or more viral antibodies in the blood, while another 25% develop acute resolving infection, 
which may or may not include a bout of hepatitis. The remaining 10% of patients develop 
chronic infection (i.e., the persistence of virus and virus antigens in the blood for more than 
6 months). In chimpanzees [12] and woodchucks [13], acute infections are characterized by the 
nearly complete clearance of virus from the blood and liver followed by seroconversion from 
surface antigen to corresponding antibody. In this case, virus is mostly cleared by non-cyto-
lytic cytokines (e.g., interferon gamma [IFNɣ] and tumor necrosis factor alpha [TNFα]) prior 
to the appearance of T and other inflammatory cells in the liver, suggesting that most virus 
clearance occurs prior to the development of acute hepatitis. Further work showed that CD4+ 
and CD8+ T cells, natural killer (NK) cells, Fas, various IFNs and corresponding receptors, and 
the TNF receptor 1 participate in virus clearance, suggesting redundant pathways inhibit HBV 
replication in the liver [14]. The subsequent contribution of a T cell response appears to clear 
virus infected cells by cytolytic mechanisms involving Fas and granzymes. In this context, 
CD4+ T cells are required to prime CD8+ T cells to facilitate virus elimination in acute infection 
[14]. When this happens in acute, resolving infection, the T cell response to HBV is vigorous, 
polyclonal and multi-specific, while among those who go on to develop chronic infection, 
adaptive immunity is relatively weak and narrowly focused, suggesting that clearance of HBV 
is T cell dependent. When T cell responses are not adequate, CLD may develop and progress 
to cirrhosis and HCC. However, CLD may spontaneously resolve at any of these stages. While 
the origin of this variability is not completely characterized, it is clear that the ability of the 
host to mount adaptive immune responses is a key element to limiting virus spread.
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3. Contributions of hepatitis B surface, core and e antigens to the 
pathogenesis of chronic infection
3.1. Hepatitis B surface antigen (HBsAg)
HBV is a small virus consisting of only four open reading frames (ORF) [15]. One ORF 
encodes a family of envelope polypeptides (Figure 1). The major envelope polypeptide, 
HBsAg, triggers neutralizing antibody which is central to virus clearance after acute expo-
sure and is the major component of the HBV vaccine [2]. HBsAg polypeptides are trans-
membrane proteins and glycoproteins that are on the envelope of virus particles, and are 
also secreted as small, spherical and variably long filamentous subviral particles that lack 
the virus nucleocapsid and HBV DNA. It is thought that these subviral particles, which 
are produced at concentrations several logs above that of infectious virus particles, absorb 
neutralizing antibody and trigger immunological tolerance, both of which promote virus 
persistence in the blood. Moreover, in patients with CLD, there does not seem to be any corre-
lation between intrahepatic HBsAg expression patterns and inflammatory infiltrates [16, 17], 
nor have HBsAg specific T cell clones been isolated from such patients [18]. In addition, T 
cell sensitization to HBsAg in acute and chronic HBV infection is usually undetectable [19], 
Figure 1. Genetic organization of HBV showing the ORFs (in color). The positions of enhancer 1 (EN1) and 2 (EN2) are 
also shown. The direct repeat 1 (DR1) and 2 (DR2) sequences at the ends of the long and short DNA strands are also 
indicted. The pregenomic RNA (3.5 kb) is greater than genome length, while the 2.1 and 2.4 kb subgenomic mRNAs 
encode surface antigen polypeptides, and the 0.7 kb mRNA encodes the X protein. Reproduced from [20] with permission.
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so while HBsAg clearance occurs in acute, resolving infections, it is not clear that it is an 
immunological target in established infections.
3.2. Hepatitis B core antigen (HBcAg)
The second ORF, or core gene, encodes the hepatitis B core antigen (HBcAg) or nucleocapsid 
protein that polymerizes as an icosahedron around the virus replication complex, the latter 
of which consists of the virus nucleic acid and HBV encoded polymerase [20]. The fact that 
the pregenomic RNA and the reverse transcribed viral DNA product are sequestered within a 
nucleocapsid means that they are not readily detected by pattern recognition receptors, (e.g., 
toll-like receptors, retinoic acid inducible gene 1 [RIG-1], and mitochondrial anti-viral signaling 
[MAVS]) that trigger innate immunity [21]. Moreover, innate immune responses do not develop 
in the liver of acutely infected chimpanzees [22], suggesting that HBV replication and spread 
may be conducted in “stealth” mode with virus nucleocapsids upon infection and again during 
virus replication. If so, then this may explain why up to 70% of acutely infected adults who 
become carriers do not develop CLD. However, carriers who develop CLD also have intrahe-
patic core antigen, suggesting that HBcAg may be an important immunological target in CLD 
[23]. Alternatively, patients with acute, resolving hepatitis show a vigorous peripheral blood 
mononuclear cell response to HBcAg that is temporally associated with the clearance of HBsAg, 
while in patients with chronic infection, T cell responsiveness to HBcAg is relatively weak, 
providing an opportunity for HBV to spread in the liver and establish a chronic infection [19].
3.3. Hepatitis B e antigen (HBeAg)
A proteolytic fragment of HBcAg, known as HBeAg, is secreted into the circulation and serves 
as a surrogate marker of virus replication. Seroconversion from HBeAg to anti-HBe is usually 
accompanied by a significant decrease in virus replication in both the liver and blood and reso-
lution of CLD [24]. The detection of HBcAg specific cytotoxic T lymphocytes (CTL) is associated 
with the clearance of virus replication, often a transient exacerbation of CLD, and seroconver-
sion to anti-HBe during the natural history of infection [24], suggesting that HBcAg is an impor-
tant virus target in CLD. HBcAg specific T cells have been detected in the peripheral blood and 
liver [18, 25] of patients with CLD, suggesting that HBcAg is an immunological target in chronic 
hepatitis B. Interestingly, HBeAg in serum may attenuate immune responses against virus 
infected liver, because some patients who develop mutations in HBV that no longer express 
HBeAg, continue to support high levels of virus replication and ongoing, CLD [26, 27]. In fact, 
HBeAg appears to be a T cell tolerogen that down-regulates immune responses against HBcAg 
[28]. HBeAg may also stimulate the appearance of regulatory dendritic cells, which would 
also suppress virus specific immunity and promote virus persistence [29] by up-regulating the 
expression of suppressor of cytokine signaling 2 (SOCS2), which in turn represses IFN signaling, 
thereby blunting innate anti-viral responses and promoting virus persistence [30]. Thus, HBeAg 
polypeptides, like subviral HBsAg particles, promote chronicity by acting as tolerogens.
3.4. Hepatitis B polymerase
The HBV encoded polymerase, encoded by a third ORF, has DNA dependent and RNA depen-
dent DNA polymerase (DNAp) activities, and RNase H activity. Upon infection, the partially 
Liver Cancer16
double stranded viral DNA is made fully double stranded by the endogenous DNAp activity 
[20] (Figure 2). The HBV genome then appears as a supercoiled mini-chromosome in the nuclei 
of infected cells, and this acts as a template for the transcription of subgenomic RNAs and a 
greater than genome length pre-genomic RNA. The latter then migrates into the cytoplasm, 
where it is packaged with the virus polymerase into nascent (“immature”) core (or nucleocap-
sid) particles, where the pregenomic RNA is reverse transcribed into minus strand DNA, with 
the latter then being used as a template for partial plus strand synthesis just prior to the bud-
ding and secretion of progeny virus (Figure 2). Some immature core particles are recycled into 
the nucleus to replenish the pool of covalently closed circular (ccc) HBV DNA. Although the 
HBV polymerase triggers antibody responses [31], there is no evidence that immune responses 
against the polymerase directly impact pathogenesis or virus persistence. However, HBV poly-
merase inhibits RIG-1 and nuclear factor kappa B (NF-ĸB) induction of IFNβ, suggesting that 
the polymerase could block innate signaling [32, 33], thereby contributing to virus persistence.
4. Relationship between persistent virus replication, integration of 
HBV DNA, and the risk for the development of HCC
There is evidence to suggest that persistent, high levels of HBV replication correlate with the 
progression of CLD to HCC [34]. However, independent work showed an elevated risk for 
HCC among patients with CLD but low virus titers [35, 36]. Other observations have shown 
no correlation between HBV DNA levels in serum (>105 copies/ml) and histological grade or 
stage of liver disease in carriers [37, 38]. In addition, it is controversial as to whether long term 
nucleoside analog therapy resulted in a decreased risk for the development of HCC [6, 35]. 
Given that HBV is not directly cytopathic [39], that carriers with high levels of HBV DNA in 
serum are often asymptomatic, and that the pathogenesis of CLD is immune mediated [17, 
Figure 2. General scheme of HBV replication. See the text for additional details. Reproduced from [20] with permission.
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40], a correlation between virus replication and CLD may contribute to, but not by itself, 
determine disease progression. Moreover, most carriers with CLD who develop cirrhosis and 
HCC have long since seroconverted from HBeAg (reflecting high levels of virus replication) 
to anti-HBe (reflecting low or undetectable virus replication), indicating that disease progres-
sion may occur at low virus titers [36]. Among patients with sustained high levels of HBV 
replication and successive bouts of CLD, there is a wave of liver regeneration following each 
episode of hepatitis to restore full liver function. At these times, fragments of HBV DNA, 
mostly encoding the HBx ORF (and sometimes the HBx plus preS/S ORFs), become integrated 
at multiple sites within host DNA [41, 42] (Figure 3). Over time, these integration events result 
in increased intrahepatic expression levels of HBx that alter patterns of host (and support 
virus) gene expression (Figure 3). HBV integrates early after infection, not only in permissive 
liver cell lines, but also in non-replicating primary human hepatocytes [43]. Many fragments 
of integrated HBV DNA encode HBx that is capable of trans-activation [44]. Although the rela-
tively low levels of HBx made from the virus mini-chromosome support virus gene expression 
and replication, it is hypothesized that as intrahepatic levels of HBx increase [45] (Figure 3), it 
epigenetically alter the expression patterns of selected host genes [46] that contribute to both 
virus persistence and to malignant transformation. Thus, the changing intrahepatic levels of 
HBx promote virus persistence and ultimately, contribute to malignant transformation [47].
4.1. Covalently closed circular HBV (ccc) DNA
Given that the current treatment of chronic hepatitis B with nucleoside analogs is not curative, 
there has been a major effort to eliminate ccc DNA [47], especially since ccc DNA is the template 
for all virus transcripts. Since nucleoside analogs do not eliminate integrated HBV templates 
or the HBV mini-chromosome, continued virus gene expression from these templates will 
drive pathogenesis toward HCC. Formation of ccc DNA is a complex process that involves 
a variety of host proteins, including several DNA polymerases [48] that could potentially 
be therapeutic targets, although this approach may be accompanied by toxicity. As outlined 
below, HBx regulates the formation, function and intracellular copy number of ccc DNA by 
several epigenetic mechanisms that involve altered expression of histone methyltransferases 
and histone deacetylases, by promoting degradation of the anti-viral restriction factor Smc5/6, 
and by increasing expression of DNA methyltransferases [48]. Anti-viral immune responses 
in which selected cytokines mediate non-cytolytic degradation of ccc DNA have also been 
documented in vitro [48, 49]. Among these, IFN alpha up-regulated expression of APOBEC3 
Figure 3. Natural history of chronic hepatitis B featuring the progressive lesions that develop in CLD compared to 
increased number of integration events, many of which produce functional HBx (modified from [53] with permission).
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nuclear deaminase resulted in a modest reduction in ccc DNA copy number via deamination 
[50]. Gene editing approaches, such as CRISPR/Cas9 have also been demonstrated to work 
in vitro and in vivo [51], but off-target effects, ability to access and act on all susceptible cells, 
and recognition of all HBV genotypes, remain to be addressed. In addition, the recent finding 
of ccc host DNA in both normal and tumor cells, as a mechanism whereby host cells regulate 
gene expression [52], implies that targeting ccc DNA may also have toxic effects on the treated 
cells whether or not they are virally infected. Thus, it is not clear whether this approach in a 
liver which is already damaged will exacerbate that damage and/or have an anti-tumor effect.
5. Contribution of HBx to pathogenesis of CLD by regulation of 
HBV replication
HBx, the trans-activation protein of HBV, trans-activates virus gene expression and replication 
in vitro [54, 55]. The contribution of this regulatory protein to virus persistence in the carrier 
state was shown in woodchucks experimentally infected with the HBV-like virus, woodchuck 
hepatitis virus (WHV). Wild type WHV readily establishes a chronic infection, characterized 
by persistent virus replication and CLD that progresses to HCC [56]. However, experimental 
infection with a mutant of WHV that does not encode woodchuck hepatitis x (WHx) antigen 
yielded no carrier state and no CLD [57, 58], suggesting that trans-activation of virus gene 
expression and replication is central to the establishment of the carrier state. Among infected 
woodchucks, there was co-staining between WHV core antigen (where virus replication takes 
place) and WHx [59, 60], while in human infection, HBx often co-existed with HBe in serum 
[61] and replication complexes (i.e., with HBcAg) in the liver [62]. Thus, HBx expression is 
associated with virus replication.
5.1. Mechanisms regulating HBV replication
At the molecular level, HBx regulates HBV replication by binding to various cellular proteins. 
For example, HBx binds to jumonji C-domain-containing 5 (JMJD5), a arginyl-hydroxylase, 
which promotes the expression of transcription factors (e.g., such as hepatocyte nuclear factors 
3 gamma and 4 alpha [HNF3G and HNF4A] and CCAAT/enhancer-binding protein alpha) that 
facilitate hepatocyte differentiation [63]. Given that HBV replicates in differentiated hepatocytes, 
the binding of HBx to JMJD5 facilitates HBV replication via epigenetic alterations in host gene 
expression. In addition, HBx promotes the formation of ccc DNA by recruiting the transcriptional 
scaffold, p300; the cAMP response element binding protein CREB; the CREB transcription factor 
binding protein, CBP; the histone acetyltransferase p300/CBP-associated factor, as well as the 
histone deactylases HDAC1, Sirt1 [48] and Sirt2 [12]. Once ccc DNA is formed, HBx up-regulates 
HBV replication, in part, by binding to cullin4-damage specific DNA binding protein (CUL4-
DDB1) ubiquitin ligase [64, 65], suggesting that HBx may function, at least in part, at the level of 
the proteasome. HBx modulates proteasome activity by direct binding to the 26S proteasomal 
subunit [66], which is responsible for degradation of HBx and several anti-viral proteins. One of 
the latter is Smc5/6, which is involved in the structural maintenance of chromosomes (i.e., genome 
stability) and DNA repair [67]. Smc5/6 and HBx bind to the HBV mini-chromosome [67, 68], 
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resulting in epigenetic changes of virus gene expression. HBx binding to CUL4-DDB1 triggers 
altered enzymatic activity of the E3 ligase CRL4, which then stimulates the ubiquitination and 
subsequent proteasomal degradation of Smc5/6 [68–70], thereby promoting virus replication. 
Other anti-viral systems, such as IFN induced APOBEC3A [50], may also be similarly degraded. 
In this context, HBV is not very good in triggering innate immunity, which may underscore why 
there are hundreds of millions of carriers worldwide [71]. As mentioned above, sequestration 
and reverse transcription of pregenomic HBV RNA in immature nucleocapsids (Figure 2) may 
block the induction of innate immunity. In addition, although HBV replication is exquisitely 
sensitive to inhibition by IFNs, HBx appears to block IFN expression and signaling [72–74], 
suggesting that both innate and adaptive immunity could be compromised, thereby permitting 
virus persistence. Under these circumstances, CLD would continue to damage the liver while 
being unable to resolve the virus infection. HBx also regulates HBV replication by stimulating 
the expression of DNA methyl-transferases (DNMTs), which suppresses HBV transcription via 
DNA methylation [75]. DNMTs also methylate tumor suppressor genes, thereby down-regulat-
ing their expression, and permitting the accumulation of mutations and chromosomal instability 
that contribute importantly to HCC. Thus, HBx regulates the activity of ccc DNA in both positive 
and negative ways, and in doing so, impacts upon the pathogenesis of CLD. The reason why it 
is important to regulate the intrahepatic levels of ccc DNA is because when virus antigens are 
greatly overproduced, they could trigger cytopathic effects (CPE), thereby limiting virus replica-
tion. For example, mutations in the preS region of the S gene prevent secretion of surface antigen 
and complete virus particles, and eventually CPE. Pre-S mutations also promote recycling of 
viral DNA into the nucleus where it results in increased levels of viral ccc DNA, which poten-
tially promotes virus persistence [76] (Figure 2). In transgenic mice overproducing HBsAg, CPE 
develops and eventually evolves into HCC [77]. Although the latter is not characteristic of HCC 
pathogenesis among human carriers, it does underscore that selected HBV mutants that may 
arise during chronic infection potentially contribute to pathogenesis via CPE.
5.2. Oxidative damage and inflammation
Although HBV is not cytopathic, HBx strongly activates NF-ĸB [78], which promotes the 
expression of many pro-inflammatory cytokines and chemokines that attenuate virus replica-
tion and contribute to the pathogenesis of CLD and HCC. For example, HBx stimulates the 
expression of IFN inducible proteins, such as the CXC chemokine IP-10 [79] which promotes 
leukocyte chemotaxis. HBx also stimulates production of interleukin-23 (IL-23) [79], which 
contributes to the maintenance and expansion of pro-inflammatory Th17 cells. Among others, 
IL-6 is up-regulated by HBx in a MyD88 manner [80], which indicates that HBx is activating 
a pro-inflammatory environment via innate immune pathways early on after infection. The 
repressive effect of IL-6 upon HBV replication is demonstrated by the fact that IL-6 treatment 
of infected cells results in the loss of HNF1a and HNF4a, both of which bind to ccc DNA. Il-6 
also redistributes signal transducers and activators of transcription 3 (STAT3) signaling from 
ccc DNA to IL-6 target genes [49]. HBx targets up-regulation of IL-18, which up-regulates 
FasL [81], which in this case blocks the killing of infected cells by CTLs. HBx also up-regulates 
tumor TNFα [82], which was shown to suppress HBcAg expression [83], thereby inhibiting 
virus replication. In addition, the pro-inflammatory IL-32 was up-regulated by HBx in a NF-ĸB 
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dependent manner [84]. This is not an exhaustive list. Many of these molecules are turned on 
as a result of HBx stimulating multiple signal transduction pathways in the cytoplasm (in 
addition to NF-ĸB), but the bigger question is trying to understand how a non-cytopathic 
virus is mediating these and other related changes in infected cells.
The fact that HBx plays a central role in HBV replication suggests that intracellular conditions 
that stimulate HBx activity would also promote the carrier state, which would be evolution-
ally selected for because it would provide a large window of time for virus to be transmitted 
to other hosts. In this context, the expression and activity of HBx is stimulated in an oxidative 
environment, since the addition of anti-oxidants to cells expressing HBx strongly diminish 
HBx trans-activation activity [85, 86]. An oxidative environment (accompanied by oxidative 
stress of cellular organelles) could be created in the infected cell by virtue of the associa-
tion of HBx with mitochondria [87]. HBx interacts with the voltage dependent anion channel 
on the outer mitochondrial membrane, altering transmembrane potential [88], resulting in 
diminished electron transport, increased free radical accumulation, including elevated lipid 
peroxidation products [89], release of calcium into the cytosol [55], and under specific circum-
stances, cell death [90]. Release of calcium into the cytosol, resulted in the activation of the 
protein tyrosine kinase 2 and Src kinase families, leading to stimulation of ras, raf, mitogen 
activated protein kinase, and Jun, which stimulate HBV transcription and replication [55]. 
HBx also induces oxidative stress in the endoplasmic reticulum, which activates the unfolded 
protein response and expression of pro-inflammatory cyclooxygenase-2 through the acti-
vating transcription factor 4 pathway [91]. Free radicals are also characteristic of immune 
responses aimed at damaging and destroying infected cells that are replicating HBV. In addi-
tion, mitochondrial associated HBx induces oxidative stress, which activates selected tran-
scription factors, such as NF-ĸB, STAT3 and activating protein 1 [86]. However, HBx is also 
known to block mitochondrial triggered cell death, not only by activation of survival [21, 92] 
and hepato-protective pathways such as NF-ĸB that over-ride apoptosis signaling, but also by 
blocking key caspases and promoting autophagy [93] and mitophagy [94]. The maintenance 
of mitochondrial and cellular homeostasis by mitophagy acts to attenuate virus induced 
apoptosis, so that on the one hand, autophagy and mitophagy promote cell survival and virus 
persistence, while simultaneous mitochondrial damage may contribute to CLD [94].
5.3. HBx and inflammation
In this chronic pro-inflammatory environment, one would expect to see a correlation between 
HBx staining and the intensity of CLD. In fact, WHx staining has been observed around 
inflammatory foci in chronically infected woodchuck livers [95], and among human carriers, 
relatively low levels of intrahepatic HBx staining was observed in patient biopsy samples 
from people with low grade hepatitis, while intense and widespread HBx staining was 
observed in patient biopsies from those with advanced fibrosis and cirrhosis [45, 96], sug-
gesting a direct correlation between HBx staining and liver damage. Independent work also 
showed low levels of HBx mRNA in the livers of patients with mild CLD (e.g., mild hepatitis), 
and much higher levels among patients with severe lesions in the liver (advanced fibrosis and 
cirrhosis) [97]. The relationship of HBx expression to disease severity is also consistent with 
the idea that when the liver regenerates following each bout of hepatitis, fragments of HBV 
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DNA encoding the HBx region (and sometimes part of the preS/S encoding gene as well) 
increasingly integrate into multiple regions of the host genome during normal host DNA 
replication, resulting in increasing accumulation of intrahepatic HBx as CLD progresses. In 
contrast, the copy number of ccc DNA per cell decreases with regeneration.
The relationship between HBx expression and CLD has been recapitulated in HBx transgenic 
mice, where the presence, frequency and distribution of HBx in the liver increase with age, 
as does liver pathology, which progressively develops from hepatitis and steatosis, to dys-
plasia and microscopic nodules of HCC, and finally to multi-nodular macroscopic HCC with 
age [98]. In this model, HBx is expressed from its own enhancer and promoter, which is not 
active until after birth when appropriate transcription factors in the liver begin to appear. 
HBx expression triggers immune responses in the absence of other HBV gene products, so it 
is likely that the pathogenesis observed is due to the impact of increasing levels of HBx upon 
host gene expression combined with immune responses directed against virus infected cells. 
There is no ccc DNA in this system, just as it is difficult to detect HBV replication among 
patients with advanced stages of CLD (i.e., cirrhosis). Thus, it is possible that early in chronic 
infection, and immune responses to virus antigens emanating from ccc DNA templates play 
an important role in triggering and sustaining immune mediated pathogenesis, but following 
bouts of CLD and liver regeneration, where the levels of virus replication decrease at the same 
time that integration of virus DNA fragments increase, pathogenesis appears to be increas-
ingly driven by one or more antigens made from integrated HBV DNA. Although cis-acting 
mechanisms have been postulated to contribute importantly to the pathogenesis of HCC in 
selected cases, the broadly distributed integration events of the HBx ORF into most chromo-
somes [99], suggests that the HBx proteins encoded by most integration events promote CLD 
and HCC in trans [47]. In this model, integration of HBV sequences would accumulate in areas 
of euchromatin and fragile sites much more frequently that at or within specific genes [100].
The model above suggests that targeting ccc DNA in HBeAg carriers with CLD may be an 
important therapeutic goal to bring about a functional (but not sterilizing) cure due to the 
presence of integrated virus DNA that express one or more virus proteins. Among anti-HBe 
carriers with advanced CLD, targeting the much lower levels of ccc DNA may not be effective 
in preventing progression to cirrhosis and HCC, because at this stage, most of the HBx made 
probably comes from integrated templates. Under these circumstances, ccc DNA may persist 
in a transcriptionally inactive form, which is consistent with the absence of HBV DNA in the 
blood, even after treatment with direct acting anti-viral agents or therapy aimed at stimulating 
immune responses against virus infected cells [101, 102]. In fact, early work already pointed out 
that seroconversion to anti-HBe is sometimes associated with the progression of CLD [103, 104], 
even though later work showed that disease progression was associated with continued rep-
lication of HBV DNA carrying one or more mutations in the core gene that blocks production 
of HBeAg [27]. These mutations were probably selected for during the natural history of infec-
tion by immune responses targeting HBcAg [105]. Although these findings suggest that CLD 
progresses in the liver supporting replication of selected virus mutants, it has also recently 
been suggested that linear HBV DNA, and not ccc DNA, is the template for integration into 
host DNA [43], from which one or more virus gene products are made, and contribute to 
pathogenesis. Thus, persistent inflammation in a chronically damaged liver may result in the 
development of HCC despite low levels or undetectable levels of virus replication.
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6. Conclusions
HBV encodes polypeptides from four ORFs that trigger corresponding immune responses 
during acute and chronic infections. When these responses are rapid, strong and multi-spe-
cific, acute, resolving infection can be achieved. When these immune responses are weak and 
of limited specificity (against few virus epitopes), the carrier state may develop. Although the 
pathogenesis of HBV is variable in different hosts, the virus encodes proteins that blunt innate 
immunity, and as a consequence, adaptive immunity is not triggered at all or to a limited 
extent. The latter causes liver damage over many years without eliminating the virus. Even 
though available treatments suppress virus replication, none are curative, and the persistence 
of viral ccc DNA sustains infection. Production of HBx regulates virus gene expression and 
replication, but over time, increased integration of HBV DNA fragments encoding HBx results 
in high levels of HBx expression that epigenetically alter the expression of numerous host 
genes that up- or down-regulate HBV replication and impact disease activity. For example, 
HBx activation of AKT decreased HBV replication, but this was accompanied by an inhibition 
of apoptosis, suggesting that HBx balances HBV replication and cell survival by stimulating 
signaling that enhance hepatocyte survival at the expense of higher levels of HBV replication 
[106]. The generation of free radicals by immune responses against virus infected cells, com-
bined with HBx mediated alterations in mitochondrial function, promote HBx activity. These 
events result in the activation of signaling pathways (e.g., AP-1 and NF-ĸB) that over-ride 
apoptosis and/or directly block the activation of critical caspases, so that whether HBx stimu-
lates or block apoptosis depends upon whether the liver is experiencing inflammation and 
oxidative stress. It also depends upon whether HBx is being expressed in normal hepatocytes, 
where apoptotic pathways could be triggered, or whether HBx is expressed at high levels in 
cells where apoptotic pathways are compromised. In addition to being pro-inflammatory, 
activated NF-ĸB protects infected cells against immune elimination. Thus, the dichotomy of 
HBx activity may be a reflection of the environment wherein HBx is expressed. Importantly, 
the epigenetic mechanisms whereby HBx regulates virus replication also have an impact on 
cell growth and survival, and many of these same alterations in host gene expression are also 
hallmarks of cancer [107], which may explain why there is such a high risk of HCC among car-
riers with CLD [11]. The common denominator is that many of the pathways and molecules 
that support HBV gene expression and replication also protect infected cells from elimination, 
and contribute centrally to malignant transformation.
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